



# Upper and lower airways response to tezepelumab in asthma patients with / without comorbid nasal polyposis

A 6 months real-life perspective

## Background




## Tezepelumab evidence



## Aim

- Trend of nasal outcomes in patients prescribed tezepelumab for asthma
- Impact on upper airways comorbidity for asthma outcomes

## Study population



## Findings

Significant, rapid improvement in all outcomes

Irrespective of:

- Sex
- BMI
- Prior biologic use
- Disease duration

↓ Oral corticosteroid use

↓ Hospitalizations

↓ Exacerbations

No difference in treatment response between asthma patients with and without CRSwNP

- Tezepelumab induced overall rapid and sustained improvements of nasal outcomes in patients with severe asthma and CRSwNP
- Lung function and clinical parameters in asthma patients improved regardless of upper airway involvement
- These findings contribute to the positioning of tezepelumab in complex patients according to a precision medicine approach